阅读说明：本技术 一种用于阴血亏虚证滋阴补血的糖类组合物 (Carbohydrate composition for nourishing yin and supplementing blood for yin and blood deficiency syndrome ) 是由 陈随清 薛淑娟 孙孝亚 郭晓凯 杨灏 马美杰 于 2020-11-19 设计创作，主要内容包括：本发明涉及用于阴血亏虚证滋阴补血的糖类组合物,可以有效解决疗效确切稳定的阴血亏虚证滋阴补血用药问题,其解决的技术方案是,由以下质量比例计的：葡萄糖︰甘露三糖︰甘露糖︰蜜二糖︰阿拉伯糖︰半乳糖︰果糖︰蔗糖︰棉籽糖︰水苏糖=0.5～1.5︰1.71～5.12︰0.03～0.08︰0.33～0.99︰0.003～0.01︰0.13～0.38︰1.02～3.06︰0.16～0.47︰0.10～0.30︰0.67～2.01作原料,混合均匀制成。本发明配伍科学合理,组分互相支持,具有增强营养,补血滋阴健身之功效有效用于阴血亏虚证滋阴补血,疗效稳定确切,服用方便效果好是阴血亏虚证滋阴补血药物上的创新,经济和社会效益巨大。(The invention relates to a carbohydrate composition for nourishing yin and supplementing blood for yin and blood deficiency, which can effectively solve the problem of yin and blood deficiency yin and blood supplementing medication with exact and stable curative effect, and adopts the technical scheme that the carbohydrate composition is calculated by the following mass ratio: glucose mannotriose, mannose, melibiose, arabinose, galactose, fructose, sucrose, raffinose, stachyose = 0.5-1.5: 1.71-5.12: 0.03-0.08: 0.33-0.99: 0.003-0.01: 0.13-0.38: 1.02-3.06: 0.16-0.47: 0.10-0.30: 0.67-2.01, and mixing uniformly. The invention has scientific and reasonable compatibility, mutually supported components, has the effects of enhancing nutrition, enriching blood, nourishing yin and building body, is effectively used for enriching yin and enriching blood for yin and blood deficiency syndrome, has stable and exact curative effect, is convenient to take, has good effect, is an innovation on yin and blood deficiency syndrome yin and blood enriching medicine, and has huge economic and social benefits.)

1. The sugar composition for nourishing yin and supplementing blood for yin and blood deficiency is characterized by comprising the following components in parts by mass: glucose: manninotriose: mannose: melibiose: arabinose: galactose: fructose: sucrose: raffinose: stachyose = 0.5-1.5: 1.71-5.12: 0.03-0.08: 0.33-0.99: 0.003-0.01: 0.13-0.38: 1.02-3.06: 0.16-0.47: 0.10-0.30: 0.67-2.01 as raw materials, and the stachyose is prepared by uniformly mixing.

2. The carbohydrate composition for nourishing yin and supplementing blood for yin and blood deficiency according to claim 1, which is prepared from the following components in percentage by mass: glucose: manninotriose: mannose: melibiose: arabinose: galactose: fructose: sucrose: raffinose: stachyose = 1: 3.44: 0.05: 0.66: 0.006: 0.25: 2.04: 0.32: 0.2: 1.34, and mixing.

3. The carbohydrate composition for nourishing yin and supplementing blood for yin and blood deficiency according to claim 1, which is prepared from the following components in percentage by mass: glucose: manninotriose: mannose: melibiose: arabinose: galactose: fructose: sucrose: raffinose: stachyose = 0.5: 1.71: 0.03: 0.33: 0.003: 0.13: 1.02: 0.16: 0.10: 0.67 as raw materials, and mixing uniformly.

4. The carbohydrate composition for nourishing yin and supplementing blood for yin and blood deficiency according to claim 1, which is prepared from the following components in percentage by mass: glucose: manninotriose: mannose: melibiose: arabinose: galactose: fructose: sucrose: raffinose: stachyose = 1.5: 5.12: 0.08: 0.99: 0.01: 0.38: 3.06: 0.47: 0.30: 2.01 as raw materials, and mixing uniformly.

5. The carbohydrate composition for nourishing yin and supplementing blood for yin and blood deficiency according to claim 1, which is prepared from the following components in percentage by mass: glucose: manninotriose: mannose: melibiose: arabinose: galactose: fructose: sucrose: raffinose: stachyose = 0.8: 4: 0.04: 0.8: 0.005: 0.25: 1.22: 0.3: 0.15: 1.8, and mixing well.

6. The carbohydrate composition for nourishing yin and supplementing blood for yin and blood deficiency according to claim 1, which is prepared from the following components in percentage by mass: glucose: manninotriose: mannose: melibiose: arabinose: galactose: fructose: sucrose: raffinose: stachyose = 1.2: 1.9: 0.07: 0.5: 0.008: 0.15: 2.28: 0.2: 0.25: 0.9, and mixing uniformly.

Technical Field

The invention relates to a medicine, in particular to a carbohydrate composition for nourishing yin and enriching blood for yin and blood deficiency.

Background

The syndrome of yin and blood deficiency is a common clinical disease, usually with yin deficiency and blood deficiency, manifested as sallow complexion, pale lips and nails, dizziness, palpitation, and irregular menstruation, and also manifested as emaciation, bone-steaming, fatigue-heat, soreness and weakness of waist and knees, dry mouth and tongue, etc. due to blood deficiency.

At present, yin nourishing and blood enriching for yin and blood deficiency syndrome is mainly treated by adopting a pharmacotherapy, and most of the traditional Chinese medicines with the effects of nourishing yin and enriching blood are combined with other blood enriching or yin tonifying medicines for treatment, such as prepared rehmannia root, Chinese angelica, prepared rehmannia root, donkey-hide gelatin, prepared rehmannia root, asparagus and the like. Because the traditional Chinese medicine prescription is mostly compound and has complex chemical components, the tonifying medicines have the side effects of easily causing excessive internal heat, stomach obstruction, loose stool and the like during the medicine taking period and are not easy to take for a long time. Therefore, it is necessary to develop a new composition of active ingredients.

Radix rehmanniae Preparata is radix rehmanniae (rehmanniae radix of Scrophulariaceae)Rehmannia glutinosaLibosch.) dried root tuber processed product is genuine medicinal material, has warm nature, has the functions of enriching blood and nourishing yin, can be used for treating blood deficiency and sallow complexion, dizziness, palpitation and insomnia, irregular menstruation, metrorrhagia and metrostaxis and other symptoms, and is often used together with other medicines for treating yin and blood deficiency. The prepared rehmannia root is a commonly used blood-enriching yin-nourishing medicine and has obvious curative effect on yin and blood deficiency, wherein the sugar is a main active ingredient. Research shows that the prepared rehmannia root oligosaccharide can promote the activity of hematopoiesis, wherein stachyose and mannotriose can obviously promote the proliferation of bone marrow cells and have the activity of enriching the blood, fructose also shows better hematopoiesis, and prepared rehmannia root has the function of nourishing yin, but the action mechanism is not clear. At present, only documents report the blood enriching effect of the prepared rehmannia root oligosaccharide and polysaccharide, but the specific formula and proportion of the saccharide components and the specific expressed efficacy of the saccharide composition are not reported so far.

Because the active ingredients of the traditional Chinese medicine are complex, the characteristics of multi-ingredient and multi-target action of the traditional Chinese medicine become the consensus of researchers, in recent years, part of pharmaceutical workers put forward the idea of taking a traditional Chinese medicine pharmacodynamic component group as a research object, simplify the complexity problem of the multiple ingredients of the traditional Chinese medicine, have the characteristics of clear pharmacodynamic substance basis, clear action mechanism, strong controllability and the like, and replace traditional Chinese medicine compound to a certain extent. The compatibility of the traditional Chinese medicines is screened as the compatibility of pharmacodynamic active component groups, so that the integration effect of the traditional Chinese medicines is clarified to become a common research mode in recent years, and the traditional Chinese medicine preparation has the advantages of definite effect, clear target position, stronger pertinence to diseases and symptoms and the like, and the traditional full-medicine compatibility mode of the prescription is an organic whole for orderly matching the medicines according to the prescription principle. The compatibility of the effective components improves the problems of complex components, unstable drug effect, unclear action link, difficult quality control and the like of the traditional prescription to a certain extent. In the face of the above situation, whether the saccharide composition is developed according to the blood enriching and yin nourishing effect of the prepared rehmannia root saccharide for yin and blood deficiency syndrome yin enriching and blood enriching can be used for representing the yin and blood deficiency syndrome yin enriching and blood enriching effect more accurately and stably, but no published report is found so far.

Disclosure of Invention

In order to overcome the defects of the prior art, the invention aims to provide the carbohydrate composition for nourishing yin and supplementing blood for yin and blood deficiency, which can effectively solve the problem of yin and blood deficiency drug administration with exact and stable curative effect.

The invention solves the technical scheme that the saccharide composition for nourishing yin and enriching blood for yin and blood deficiency is prepared from the following components in parts by mass: glucose mannotriose, mannose, melibiose, arabinose, galactose, fructose, sucrose, raffinose, stachyose = 0.5-1.5: 1.71-5.12: 0.03-0.08: 0.33-0.99: 0.003-0.01: 0.13-0.38: 1.02-3.06: 0.16-0.47: 0.10-0.30: 0.67-2.01, and mixing uniformly.

The invention has scientific and reasonable compatibility, mutually supported components, has the effects of enhancing nutrition, enriching blood, nourishing yin and building body, is effectively used for enriching yin and enriching blood for yin and blood deficiency syndrome, has stable and exact curative effect, is convenient to take, has good effect, is an innovation on yin and blood deficiency syndrome yin and blood enriching medicine, and has huge economic and social benefits.

Detailed Description

The following detailed description of the embodiments of the present invention will be given with reference to the accompanying specific cases and examples.

In particular, the invention may be embodied as set forth in the following examples.

Example 1

The invention relates to a carbohydrate composition for nourishing yin and supplementing blood for yin and blood deficiency, which is calculated by the following mass ratio: glucose mannotriose, mannose, melibiose, arabinose, galactose, fructose, sucrose, raffinose, stachyose = 1: 3.44: 0.05: 0.66: 0.006: 0.25: 2.04: 0.32: 0.2: 1.34, and mixing them uniformly.

Example 2

The invention relates to a carbohydrate composition for nourishing yin and supplementing blood for yin and blood deficiency, which is calculated by the following mass ratio: glucose mannotriose, mannose, melibiose, arabinose, galactose, fructose, sucrose, raffinose, stachyose = 0.5: 1.71: 0.03: 0.33: 0.003: 0.13: 1.02: 0.16: 0.10: 0.67, and mixing them uniformly.

Example 3

The invention relates to a carbohydrate composition for nourishing yin and supplementing blood for yin and blood deficiency, which is calculated by the following mass ratio: glucose mannotriose, mannose, melibiose, arabinose, galactose, fructose, sucrose, raffinose, stachyose = 1.5: 5.12: 0.08: 0.99: 0.01: 0.38: 3.06: 0.47: 0.30: 2.01, and mixing them uniformly.

Example 4

The invention relates to a carbohydrate composition for nourishing yin and supplementing blood for yin and blood deficiency, which is calculated by the following mass ratio: glucose mannotriose, mannose, melibiose, arabinose, galactose, fructose, sucrose, raffinose, stachyose =0.8, 4, 0.04, 0.8, 0.005, 0.25, 1.22, 0.3, 0.15, 1.8, and mixing uniformly.

Example 5

The invention relates to a carbohydrate composition for nourishing yin and supplementing blood for yin and blood deficiency, which is calculated by the following mass ratio: glucose mannotriose, mannose, melibiose, arabinose, galactose, fructose, sucrose, raffinose, stachyose = 1.2: 1.9: 0.07: 0.5: 0.008: 0.15: 2.28: 0.2: 0.25: 0.9 as raw materials, and mixing them uniformly.

The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention. In addition, in the specific implementation, the mass ratios in the above examples can be converted into parts by mass ratio for convenient operation, and the saccharide composition for nourishing yin and supplementing blood for yin and blood deficiency syndromes disclosed by the invention in example 1 is calculated according to the following mass ratios: glucose, mannotriose, mannose, melibiose, arabinose, galactose, fructose, sucrose, raffinose, stachyose, and stachyose = 0.8: 4: 0.04: 0.8: 0.005: 0.25: 1.22: 0.3: 0.15: 1.8.

The sugar composition is directly converted into the sugar composition for nourishing yin and enriching blood for yin and blood deficiency syndrome, and comprises the following components in parts by weight: 800 parts of glucose, 4000 parts of manninotriose, 40 parts of mannose, 800 parts of melibiose, 5 parts of arabinose, 250 parts of galactose, 1220 parts of fructose, 300 parts of cane sugar, 150 parts of raffinose and 1800 parts of stachyose. Other examples are analogized, and accordingly, the components of the invention part can be modified into the following components according to the mass part ratio: 500-1500 parts of glucose, 1710-5120 parts of mannotriose, 30-80 parts of mannose, 330-990 parts of melibiose, 3-10 parts of arabinose, 130-380 parts of galactose, 1020-3060 parts of fructose, 160-470 parts of sucrose, 100-300 parts of raffinose and 670-2010 parts of stachyose, and the like.

The invention relates to a creative saccharide composition prepared by field tests and experiments according to the composition of effective active ingredients of prepared rehmannia root polysaccharide, which is used for preparing the saccharide composition for treating yin and blood deficiency syndrome yin nourishing and blood enriching, and the compatibility of traditional Chinese medicine raw materials is screened as the compatibility of pharmacodynamic active ingredient groups, so that the problems of complex components, unstable efficacy, unclear action links and difficult quality control of the traditional prescription are solved, and the related data are as follows:

first, the basis and acquisition of the technical scheme

1. Screening saccharide effective substances to determine the content of sucrose, raffinose, stachyose and fructose

Content determination by HPLC chromatography:

chromatographic conditions

A chromatographic column: inertsil NH₂(5 μm, 4.6X 250 mm); the mobile phase is acetonitrile to water (70: 30); using a differential refractive detector; the flow rate was 1 mL/min.

Preparation of control solutions

Precisely weighing 5.06mg of raffinose, 3.41mg of sucrose, 9.83mg of stachyose and 4.97mg of fructose, placing the materials in a 1mL volumetric flask, and adding water to dissolve the materials to a scale. The concentrations of raffinose, sucrose, stachyose and fructose as reference substances were 5.06mg/mL, 3.41mg/mL, 9.83mg/mL and 4.97mg/mL, respectively.

Preparation of test solution

Accurately weighing 1.50g of prepared rehmannia root sample into a conical flask, weighing 50mL of distilled water, refluxing for 2h, taking out, cooling, complementing weight, filtering, taking 20mL of subsequent filtrate, respectively extracting with equivalent petroleum ether and ethyl acetate twice, and taking the lower layer solution to pass through a 0.22 mu m microporous filter membrane for later use.

2. Determination of glucose, galactose, mannotriose, melibiose, arabinose and mannose content

Content determination by HPLC chromatography:

chromatographic conditions

A chromatographic column: waters Xbridge shield C18 chromatographic columns (250X 4.6mm, 5 μm); glucose and galactose mobile phases: 20mM ammonium acetate in water (B) and acetonitrile (A); mannose, melibiose, arabinose and mannose mobile phases: 0.1% formic acid (B) and acetonitrile (A). The gradient elution procedure is shown in Table 1, with a flow rate of 1 mL/min. A detector: shimadzu SPD-20A, wavelength: 245 nm.

Table 1 mobile phase composition table

Time (min)	Flow phase ratio
		0-5	0.1% formic acid (B): acetonitrile (A) (83: 17)
5-15	B：A（83：17）→B：A（80：20）
		15-20	B：A（80：20）→B：A（77：23）
20-25	B：A（77：23）→B：A（76：24）
		25-30	B：A（76：24）→B：A（83：17）
30-32	B：A（83：17）

Preparation of control solutions

4.86mg of glucose, 4.98mg of galactose, 4.79mg of mannotriose, 4.79mg of mannose, 5.41mg of melibiose and 8.29mg of arabinose were precisely weighed and placed in a 1mL volumetric flask, and dissolved to the scale by adding water. The concentrations of glucose, galactose, mannotriose, mannose, melibiose and arabinose as control substances were 4.86mg/mL, 4.98mg/mL, 4.79mg/mL, 5.41mg/mL and 8.29mg/mL, respectively.

PMP derivatization of test solutions

Taking 100 mu L of sample solution, sequentially adding 100 mu L, 0.3mol/L NaOH solution and 0.5mol/L PMP (1-phenyl-3-methyl-5-pyrazolone) methanol solution into a centrifuge tube, uniformly mixing, and reacting at 70 ℃ for 30 min. After cooling, the reaction mixture was reacted with an equivalent amount of 0.3mol/L HCl solution, and then centrifuged and extracted with 400. mu.L of chloroform for 10min, and the upper layer solution was collected for HPLC analysis.

3. Results of measurement of 10 kinds of sugars

5 parts of prepared rehmannia root samples (PRR-1 to PRR-5) were prepared according to the above preparation method of the test sample solution, and each of the prepared rehmannia root samples was injected into a high performance liquid chromatograph, and the content of 10 kinds of sugars in the sample was measured, and the range of the ratio of each component to glucose was calculated with the average ratio of glucose as a reference, with 50% of the average ratio as the lowest ratio, and 150% of the average ratio as the highest ratio, and the results are shown in Table 2.

TABLE 2 measurement results of contents of 10 kinds of saccharides in prepared rehmannia root samples

Sample (I)	PRR-1	PRR-2	PRR-3	PRR-4	PRR-5	Mean value of	Average ratio	Range of ratios
									Manotriose	22.01%	22.03%	23.27%	22.04%	23.97%	22.67%	3.41	1.71-5.12
Mannose	0.32%	0.35%	0.31%	0.33%	0.35%	0.33%	0.05	0.03-0.08
									Melibiose	4.22%	4.56%	4.59%	4.34%	4.22%	4.39%	0.66	0.33-0.99
Arabinose	0.04%	0.04%	0.03%	0.03%	0.04%	0.04%	0.006	0.003-0.01
									Glucose	5.33%	7.23%	7.68%	6.41%	6.61%	6.6%	1	0.5-1.5
Galactose	1.78%	1.70%	1.77%	1.45%	1.61%	1.66%	0.25	0.13-0.38
									Fructose	8.40%	13.05%	18.89%	15.30%	12.17%	13.56%	2.04	1.02-3.06
Sucrose	1.46%	1.95%	1.67%	3.81%	1.43%	2.06%	0.31	0.16-0.47
									Cotton seed candy	1.14%	1.19%	1.04%	1.75%	1.52%	1.33%	0.2	0.10-0.30
Stachyose	8.66%	10.03%	9.15%	7.36%	9.32%	8.91%	1.34	0.67-2.01

Repeated experimental measurements according to the results of table 2 determined that the saccharide compositions of the present invention are in the following mass ratios: glucose: manninotriose: mannose: melibiose: arabinose: galactose: fructose: sucrose: raffinose: stachyose = 0.5-1.5: 1.71-5.12: 0.03-0.08: 0.33-0.99: 0.003-0.01: 0.13-0.38: 1.02-3.06: 0.16-0.47: 0.10-0.30: 0.67-2.01, and the drug effect experiment of the saccharide composition provided by the embodiment shows that the effect is very good.

Second, animal experiment

1. Animal experiment for blood deficiency syndrome

1.1 animal groups

120 SD rats, female, 180-.

1.2 establishment of blood deficiency model

Except for a blank control group (a blank group for short), each group of rats respectively subcutaneously injects 20mg/Kg and 10mg/Kg of an Acetylphenylhydrazine (APH) normal saline solution on the 1 st and 4 th days after the experiment starts, and after subcutaneously injecting APH normal saline for 2h on the 4 th day, the 4 th to 7 th days are intraperitoneally injected with 20mg/Kg of a Cyclophosphamide (CTX) normal saline solution every day, and simultaneously the blank control group respectively subcutaneously and intraperitoneally injects the same amount of normal saline solution to establish a blood deficiency syndrome model.

1.3 test methods

On the first day of experiment, the low-dose group of sugar composition (example 2) was drenched with 204.76mg of low-dose sugar composition mixture per mL of sugar-containing composition (204.76 mg/mL), the medium-dose group of sugar composition (example 1) was drenched with medium-dose sugar composition mixture per mL of sugar-containing composition 409.52mg (409.52 mg/mL), the high-dose group of sugar composition (example 3) was drenched with 819.08mg of high-dose sugar composition mixture per mL (819.08 mg/mL), the remaining monosaccharide groups were drenched with the respective sugar ratios of the high-dose sugar compositions, the drenched volume was 1mL/100g, and the control group and the model group were drenched with distilled water in equal amounts, once a day, for 15 consecutive days.

1.4 peripheral blood index and thymus and spleen index detection

After 1 hour of the last administration, each rat's orbit was bled and the values of Red Blood Cells (RBC), Hemoglobin (HGB), White Blood Cells (WBC), and Hematocrit (HCT) in the peripheral blood were measured with a full-automatic hematology analyzer. Taking thymus and spleen gland of rat, and calculating their ratio to body mass (i.e. thymus and spleen index), wherein thymus index = thymus (mg)/weight of mouse (g) × 100%, and spleen gland index = spleen gland (mg)/weight of mouse (g) × 100%

1.5 statistical analysis

SPSS20.0 statistical software was used for One-Way ANOVA (One-Way ANOVA) analysis of variance, all experimental data were taken ±sIs represented by P<A difference of 0.05 is statistically significant.

1.6 results of the experiment

The results of the statistical treatment are shown in Table 3

TABLE 3 comparison of peripheral hemograms and thymus and spleen glands in rats of various groups: ( ±s，n=8）

Group of

WBC/×109·L-1

RBC/×1012·L-1

HGB/g·L-1

HCT（%）

Thymus index (mg/g)

Spleen index: (mg/g）

Blank group

13.83±2.26

7.75±0.31

146±4.76

44.8±1.16

2.56±0.4

2.45±0.24

Model set

6.88±4.06##

2.3±0.72##

56.2±18.82##

18.98±6.1##

0.67±0.16##

9.15±1.38##

Low dose group of sugar compositions

7.44±1.58

6.09±0.37**

146±4.47*

46.64±1.81**

1.38±0.19

3.04±0.62*

Dosage group in sugar composition

10.25±2.05*

6.39±0.3**

148.17±4.95**

47.67±1.35**

1.63±0.29*

2.79±0.61**

High dose set of sugar compositions

12.5±1.64**

6.72±0.58**

160.25±10.92**

48.05±3.82**

1.72±0.24**

2.59±0.17**

Glucose

6.72±1.21

2.12±0.12

54.4±1.12

17.72±3.2

0.74±0.25

9.42±0.15

Manotriose

7.12±0.26

4.45±0.69

58.3±2.15

29.68±1.6

0.98±0.56

8.45±0.25

Mannose

6.81±0.85

2.36±0.21

59.5±1.52

16.85±5.2

0.56±0.13

9.04±0.14

Melibiose

7.09±0.52

3.89±0.43

72.8±1.38

27.12±2.5

0.71±0.25

9.12±0.25

Arabinose

6.62±1.34

2.41±0.25

59.8±2.58

19.45±1.3

0.62±0.41

9.23±0.28

Galactose

6.76±0.76

2.43±0.18

60.01±2.17

20.14±1.9

0.68±0.15

9.18±0.12

Fructose

7.24±0.81

4.81±0.32

65.24±3.59

28.45±5.2

0.78±0.23

7.23±1.25

Sucrose

6.99±1.34

4.09±0.15

85.73±2.86

27.15±2.9

0.71±0.15

8.76±1.56

Cotton seed candy

7.02±0.61

2.02±0.42

82.16±1.52

25.47±3.4

0.73±0.13

8.12±0.59

Stachyose

7.06±0.75

4.26±0.37

91.58±4.23

20.25±1.2

0.69±0.22

8.52±1.20

As is clear from Table 3, the white blood cell count, red blood cell count, hemoglobin content, hematocrit, and thymus index of the model control rats were significantly decreased (P < 0.01), while the spleen gland index was significantly increased (P < 0.01), as compared to the blank control rats. Compared with the model group, the number of red blood cells and the hematocrit of the sugar composition low-dose group are obviously increased (P < 0.01), and the hemoglobin content and the spleen index are increased (P < 0.05); the number of erythrocytes, the hematocrit and the hemoglobin content of a dose group in the sugar composition are all obviously increased (P is less than 0.01), the white blood cell and thymus index is increased (P is less than 0.05), and the spleen index is obviously reduced (P is less than 0.01); the number of red blood cells, hematocrit, hemoglobin content, white blood cells and thymus index of the sugar composition high-dose group are all obviously increased (P is less than 0.01), and the spleen index is obviously reduced (P is less than 0.01). Other monosaccharide solutions had less effect on white blood cell count, red blood cell count, hemoglobin content, hematocrit, and thymus and spleen gland indices, and the results are shown in table 3. As can be seen from Table 3, the saccharide composition provided by the invention has a significant effect of improving the number of red blood cells, the hematocrit, the hemoglobin content, the white blood cell and the thymus index of a blood-deficiency rat, and a significant effect of reducing the spleen index.

2. Animal experiment for kidney yin deficiency syndrome

2.1 animal groups

Animal grouping method under animal experiment item of blood deficiency syndrome 1.1 grouping method.

2.2 establishment of model of Yin deficiency syndrome

Except for a blank control group (referred to as a blank group), rats in each group were administered 150 mg/Kg thyroxine tablets per day for 21 consecutive days. The blank group was given an equal amount of distilled water daily. The general state of the animal's hair, activity, morphology, etc. was observed during molding.

2.3 test methods

On the first day of experiment, the low-dose group of sugar composition (example 2) was drenched with 204.76mg of low-dose sugar composition mixture per mL of sugar-containing composition (204.76 mg/mL), the medium-dose group of sugar composition (example 1) was drenched with medium-dose sugar composition mixture per mL of sugar-containing composition 409.52mg (409.52 mg/mL), the high-dose group of sugar composition (example 3) was drenched with 819.08mg of high-dose sugar composition mixture per mL (819.08 mg/mL), the remaining monosaccharide groups were drenched with the respective proportions of sugars in the high-dose sugar composition, the drenched volume was 1mL/100g, and the control group and the model group were drenched with distilled water in equal amounts, once a day, and continuously for 4 weeks.

2.4 blood index detection

After 1h of the last administration, each rat abdominal aorta was bled, serum and plasma were separated, and the serum was assayed for the content of triiodothyronine (T3), thyroxine (T4), testosterone (T), estradiol (E2), cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP).

2.5 statistical analysis

SPSS20.0 statistical software was used for One-Way ANOVA (One-Way ANOVA) analysis of variance, all experimental data were taken ±sIs represented by P<A difference of 0.05 is statistically significant.

2.6 results of the experiment

The results of the statistical treatment are shown in Table 4.

TABLE 4 results of measurement of T3, T4, T, E2 in serum and cAMP and cGMP in plasma (C)±SD）

T4（ng/mL）

T3（ng/mL）

T（nmol/L）

E2（pmol/L）

cAMP（nmol/L)

cGMP（nmol/L）

Normal group

880.83±120.71

14.82±1.74

22.22±2.25

44.88±7.24

15.74±3.08

67.79±5.65

Model set

984.48±86.79**

14.94±2.31

19.58±3.58*

50.79±8.59

18.14±1.78*

52.63±6.47**

Low dose group of sugar compositions

912.32±103.24

14.97±1.32

22.12±0.89#

49.76±5.23

16.12±1.25

62.34±5.65##

Dosage group in sugar composition

896.34±95.48#

14.76±1.63

22.58±3.16#

49.32±3.24

15.66±2.16##

65.41±2.56##

High dose set of sugar compositions

885.12±98.41##

14.43±1.01

22.75±1.58#

46.13±4.15

15.52±2.45##

66.12±6.42##

Glucose

1002.17±94.68

15.21±2.12

18.65±1.69

51.26±3.68

18.56±1.96

51.36±2.57

Manotriose

962.12±125.46

14.97±1.08

19.43±0.96

50.36±7.16

18.06±1.45

52.48±4.35

Mannose

996.14±88.43

14.99±0.75

18.25±1.75

51.78±6.28

19.24±2.06

51.43±5.14

Melibiose

974.35±86.52

14.89±1.74

19.10±2.18

49.98±5.27

18.25±2.85

52.29±4.19

Arabinose

1004.12±102.41

15.16±0.97

18.16±2.35

50.34±4.26

18.96±1.63

51.82±6.18

Galactose

998.16±76.89

15.04±2.13

18.53±1.46

50.88±7.63

18.42±2.45

50.29±4.29

Fructose

968.78±68.37

14.93±1.50

19.62±1.73

49.96±5.64

18.12±2.37

52.27±4.27

Sucrose

985.64±96.58

14.86±0.68

19.52±0.63

50.16±6.85

18.56±1.86

53.63±3.67

Cotton seed candy

972.68±103.59

14.91±1.30

19.16±1.28

50.73±7.46

18.72±2.15

52.94±5.13

Stachyose

968.29±93.76

14.89±0.91

19.76±1.76

49.92±7.37

18.16±3.13

53.75±4.82

As is clear from Table 4, the level of thyroxine (T4) is significantly increased (P < 0.01) and the level of cyclic adenosine monophosphate (cAMP) is increased (P < 0.05) in the model control group rats compared with the blank control group rats; the content of cyclic guanosine monophosphate (cGMP) is obviously reduced (P is less than 0.01), and the content of testosterone (T) is reduced (P is less than 0.05). Compared with a model group, the sugar composition has obviously increased cyclic guanosine monophosphate (cGMP) content (P < 0.01) and testosterone (T) content (P < 0.05); a significant increase in the amount of cyclic guanosine monophosphate (cGMP) (P < 0.01), a significant decrease in the amount of testosterone (T) (P < 0.05), a significant decrease in cyclic adenosine monophosphate (cAMP) (P < 0.01), and a decrease in the amount of thyroxine (T4) (P < 0.05) in the sugar composition; the high-dose of the sugar composition has obviously increased cyclic guanosine monophosphate (cGMP) content (P < 0.01), while testosterone (T) content is increased (P < 0.05), cyclic adenosine monophosphate (cAMP) and thyroxine (T4) are obviously reduced (P < 0.01). Other monosaccharide solutions had less effect on the levels of triiodothyronine (T3), thyroxine (T4), testosterone (T), estradiol (E2), cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), with the results shown in table 4. As can be seen from Table 4, the saccharide composition provided by the invention has a significant effect of improving cyclic adenosine monophosphate (cAMP) and testosterone (T) of rats with yin deficiency, and a significant effect of reducing the content of cyclic adenosine monophosphate (cAMP) and thyroxine (T4).

Third, clinical trial

On the basis of ensuring the safety of animal experiments, clinical experiments show that the method has very good beneficial technical effects, and the related data are as follows:

1. criteria for selecting cases

The clinical manifestations of yin and blood deficiency usually include yin deficiency and blood deficiency, and the symptoms of sallow complexion, pale lips and nails, dizziness, palpitation, irregular menstruation, emaciation, bone-steaming, fatigue-heat, soreness and weakness of waist and knees, dry mouth and tongue, etc. caused by blood deficiency.

All the above symptoms were used as criteria for selecting cases. 2. Diagnostic criteria

The patients with the symptoms of sallow complexion, pale lips and nails, dizziness, palpitation, irregular menstruation, emaciation, bone-steaming fatigue, soreness and weakness of waist and knees, dry mouth and tongue and the like which have the case selection standard can be diagnosed as suffering from yin and blood deficiency in the traditional Chinese medicine and need to be treated by using medicines (index test without western medicine diagnosis).

3. Treatment regimens

Take example 1 as an example

The saccharide composition provided in example 1 was added with water to make the mass concentration of 409.52mg/mL, and administered 2-3 times a day, 20-30mL each time, 30 days as a treatment course, and the treatment effect was counted for 2 treatment courses (halving of children).

4. Therapeutic efficacy assessment criteria (Note: the existence of therapeutic efficacy assessment criteria in TCM, if any, please give, the criteria given below are those inferred by the agent based on the conventional, not necessarily accurate

And (3) curing: the symptom disappears, the complexion is ruddy, and the symptom of yin deficiency disappears, and is confirmed by the diagnosis of the traditional Chinese medicine.

The method has the following advantages: the symptoms are obviously improved, and the traditional Chinese medicine diagnosis confirms that the treatment is still continued by taking the medicine.

And (4) invalidation: the symptoms are not improved, and even aggravated.

5. Statistical treatment

SPSS20.0 statistical software was used for One-Way ANOVA (One-Way ANOVA) analysis of variance, all experimental data were taken ±sIs represented by P<A difference of 0.05 is statistically significant.

118 patients with yin and blood deficiency are treated by the medicine for enriching blood and nourishing yin, wherein 60 men and 58 women have age of 5-70 years and the disease duration is 1-12 months (including patients who have no obvious effect by adopting other medicines), 83 patients are cured by statistical treatment, the cure rate is 70.3%, the effective rate is 33 patients accounting for 28%, the ineffective rate is 2 patients accounting for 1.7%, and no adverse reaction is found in experiments.

On the basis of the above experiments on the embodiments, experiments on other embodiments have also been carried out, and all the same and similar results are obtained, which are not listed here. No adverse reaction is found in the experiment, which shows that the medicine is safe and the curative effect is stable and reliable.

6. Conclusion

The above experiments clearly show that the saccharide composition has obvious effects of improving the number of erythrocytes, the hematocrit, the hemoglobin content, the white blood cell and the thymus index of rats with blood deficiency syndrome, reducing the spleen index, improving the cyclic adenosine monophosphate (cAMP) and the testosterone (T) of rats with yin deficiency syndrome, and reducing the cyclic adenosine monophosphate (cAMP) and the thyroxine (T4) content, can be used for treating the blood deficiency syndrome with blood deficiency syndrome, has the effective rate of 98% in the existing experiments through clinical experiments, has no toxic or side effect, has good effect which is not expected, and has the effects of enriching blood and nourishing yin, and has clear effect, The medicine has clear target and stronger pertinence to diseases and symptoms, changes the whole medicine compatibility mode of the traditional prescription, and improves the problems of complex components, unstable medicine effect, unclear action link, difficult quality control and the like of the traditional prescription to a certain extent through the compatibility of effective active ingredients. Is a great innovation of the medicine for enriching blood and nourishing yin for treating yin and blood deficiency, develops a new way for treating yin and blood deficiency, and has great economic and social benefits.